
What is the background of the co-creation program?
Based on its sustained R&D investment, Sangsin Pharmaceutical has expanded and relocated its research center to Magok-dong, Gangseo-gu, Seoul Special City in 2021 in order to expand its advanced research facilities and strengthen its R&D infrastructure. The newly reborn Sangsin Pharmaceutical Research Center is expected to become a C&D center (connected collaboration and development center) for new drug development through a large-scale expansion of its research infrastructure including excellent human resources and all-round open innovation with domestic and overseas research institutions and pharmaceutical biotech companies that have technological competitiveness. It will function as a C&D center (connected collaboration and development center) for new drug development through all-round open innovation with domestic and international research institutions and pharmaceutical biotech companies with competitive technologies.
Through this, Sanshin Pharmaceutical Research Center will develop innovative global new drugs and source technologies for unmet medical needs and lead Sanshin Pharmaceutical's quantum jump to a global pharmaceutical company.
We look forward to receiving proposals from startups with excellent technology that we can collaborate with and grow with as Sanshin Seiyaku makes the leap to becoming a global pharmaceutical company. Thank you very much.
Outline of "Sanshin Pharmaceutical Co.
▶︎ Application deadline: Sunday, August 18, 2024 23:00
▶︎ Target companies: all domestic and international startups. Any industry.
▶︎ Participation fee: Free
▶︎ Sponsored by Sanshin Pharmaceutical Co.
What we want to achieve with the Co-Creation Program
1. antibody-based new drug development technology
- Sanshin Pharmaceutical was founded with the dignity of human life as its corporate spirit. To protect human health through the development of new drugs and to eradicate diseases at their root, Sanshin Pharmaceutical is constantly challenging itself to develop superior drugs. Based on these beliefs, we are looking for startups with ideas that we can collaborate with.
- Desired Collaboration
- Human Antibody Library Production Technology
- Antibody Discovery Technology
- Antibody Engineering Technology
- Antibody Optimization Technology
- Double and triple antibody production technology
- Antibody culture/purification/analysis technology
- ADC and dual specific ADC fabrication technology
- Various other antibody-related ideas
2. new drug development technology based on small molecule compounds
- Desired Collaboration
- Research and development of innovative small molecule anti-cancer drugs
- Research and development of innovative small molecule fibrosis treatments
- Research and development of small molecule innovative allergy treatments
- ADC Linker Technology
*Linker technology development, linker drug binding technology, stability evaluation, manufacturing and production technology, etc. - TPD Development Technology
Protein degradation target discovery and validation technology, molecular glue-PROTAC design technology, TPD synthesis and optimization technology, etc. - Other low-molecular-weight compound-based therapeutic agents or related technologies
3. new drug development technology based on artificial intelligence
- Desired Collaboration
- Artificial intelligence-based small molecule drug design platform
- Artificial intelligence-based protein new drug design platform
- AI-based new drug target discovery and validation technology
- AI-based drug screening and virtual simulation technologies and services
- Other technologies related to new drug development utilizing AI
Sanshin Seiyaku's management resources (resources) that startups can utilize
Provision of office space in the Asatani Research Center and use of its equipment
Offices provided in the Asatani Research Center
Provision of welfare at the level of Sanjin employees (breakfast - lunch provided, exercise facilities and other welfare facilities provided)
Equipment available at the Asatani Research Center (NMR, MPLC, HPLC, LC-MS/MS, SPR, FACs, fluorescence microscope, SPF-grade animal room, fluidized bed granulator, dosing machine, hydrodynamic dryer, etc.)
interpoint (interword separation)Research funding support and SI investment through the National R&D Agenda
Research funding support through joint execution of national R&D projects
Strategic investment (SI) is possible due to the potential for technological growth
Collaboration with cooperating investment companies such as Asatani Weconomy Fund
Raw material pharmaceuticals and EU-GMP-grade injectable production facilities are available.
Utilizing the Gosong Plant and Konan Plant facilities, the company is able to produce raw material pharmaceuticals and EU-GMP-grade injectable drugs.
interpoint (interword separation)Advisory use of new drug development specialists available
Advisory access to professional personnel with specialized experience and knowledge of clinical, development, and marketing issues in the pharmaceutical sector
Sanshin Seiyaku's domestic and global network can be shared.
Global network can be shared through BIO-US/EU along with the Korea-US network
Enthusiasm for the Program
Sanshin Seiyaku and Creww Korea are looking for Japan's best startups to participate in the "Sanshin Seiyaku (Co., Ltd.) Open Innovation".
We look forward to receiving applications from startups who wish to grow with Sanshin Seiyaku through this program!
About Sanshin Pharmaceutical
"A company that pioneers healthy living for mankind with a creative spirit and moves forward for a prosperous future.
Established in 1968, Sanshin Pharmaceutical is a mid-sized Korean pharmaceutical company. The company has over 770 members and generates annual sales of approximately 300 billion won through the sale of over-the-counter drugs and specialty drugs in various medical fields.
The headquarters is located in Hongdae, Seoul, Republic of Korea, with factories in Osong, Chungcheongbuk-do, and Hyangnam, Gyeonggi-do, that produce raw material pharmaceuticals and finished products. The research center in charge of research and development of new drugs is located in Asagok, Seoul.
In December 2021, Sanshin Pharmaceutical completed construction of the Maya Research Center with a budget of 40 billion won. The Magok Research Center has the resources and capabilities to independently carry out the entire process of new drug development from the initial stage to the final clinical and licensing stages. It also has an in-house AI drug development team that actively utilizes AI in new drug development. Our focus areas are immuno-cancer, non-alcoholic steatohepatitis (MASH), and allergic diseases, and we are also conducting research on novel modalities of ADC (antibody-drug conjugate) and TPD (targeted proteolysis).
Through open innovation, the Asagaya Research Center has conducted joint research with more than 10 Korean and foreign venture companies since 2022.
We are looking forward to your support as we work together and grow as a global pharmaceutical company through the development of innovative new medicines.
https://www.samjinpharm.co.kr/front/en/main/index.asp









